The 20.7% weight loss with the high-dose of semaglutide bested the mean reduction of 17.5% seen with semaglutide 2.4 mg, according to Novo Nordisk.
All News
Advertisement
Advertisement
Your daily dose of the clinical news you may have missed.
The DEA action includes 3 new telehealth rules that make permanent several flexibilities enacted during the pandemic and also establish new protections for patients.
Mineralys Therapeutics also expects topline data from its phase 2 study of lorundrostat for the treatment of uncontrolled hypertension or resistant hypertension when used as an add-on therapy.
The effective approach to identifying risk for the disruptive cognitive issues holds promise for development of early intervention to mitigate decline.
The Florey Dementia Index showed robustness across different cohorts but more testing is needed, researchers reported.
The agency estimates that limiting nicotine levels could lead to 1.8 million fewer tobacco-related deaths by 2060 and health care savings of $1.1 trillion a year over the next 40 years.
"Glucocorticoid therapy in classic congenital adrenal hyperplasia: traditional and new treatment paradigms," offers an in-depth look at the disorder and promising therapies.
Caissa Troutman, MD, stresses the importance of building trust with patients through active listening and consistent, non-judgmental communication.
Your daily dose of the clinical news you may have missed.
Advertisement
Marketed as Omvoh, the therapy is already approved as a first-in-class treatment for moderately to severely active ulcerative colitis.
Early proof-of-concept phase 1a data from the trial is anticipated in the third quarter of 2025.
The USPSTF recommends all women ages 65 and older and at-risk postmenopausal women under 65 should be screened for osteoporosis.
More than half of study participants receiving the dual incretin agonist had weight loss of 20% or greater, with no evidence of a plateau and only mild AEs.
Elinzanetant VMS update: As Positive Results Pile Up, Bayer Readies for Menopause Treatment’s Future
FDA action date set for July 26, 2025.
Your daily dose of the clinical news you may have missed.
Annual incidence of dementia will double in White adults and triple among Black adults. The updated estimates place the lifetime risk of developing dementia after age 55 at 42%.
Obesity medicine expert Caissa Troutman, MD, suggests using annual physicals as a "gateway" to identify patients with obesity with elevated blood pressure.
A new analysis of patient reported outcomes from the PATHFINDER study indicate the potential clinical benefit of early cancer detection.
Advertisement
Advertisement
Advertisement
